Comparative Pharmacology
Head-to-head clinical analysis: SAXAGLIPTIN versus TRADJENTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAXAGLIPTIN versus TRADJENTA.
SAXAGLIPTIN vs TRADJENTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Saxagliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), which prolongs the action of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It slows the inactivation of incretin hormones GLP-1 and GIP, increasing their levels, which stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner.
2.5 mg or 5 mg orally once daily irrespective of meals.
5 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateSaxagliptin + Gatifloxacin
"Saxagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSaxagliptin + Rosoxacin
"Saxagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSaxagliptin + Levofloxacin
"Saxagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSaxagliptin + Trovafloxacin
"Saxagliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal half-life: 2.5 hours; accounts for DPP-4 inhibition duration despite rapid clearance.
Terminal elimination half-life is approximately 12.5 hours at steady state, consistent with once-daily dosing and supporting 24-hour DPP-4 inhibition.
Renal (75% as unchanged drug and metabolites; 25% as unchanged drug in urine) and fecal (22% as metabolites).
Approximately 85% of the dose is excreted in feces (mostly as unchanged parent drug) and about 5% in urine (largely as metabolites). Biliary excretion accounts for the majority of fecal elimination.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor